CML patients with stable response may safely decrease dose of TKI
3 Dec 2016
CML patients with stable response may safely decrease dose of TKI
Novel antibody boosts responses in newly diagnosed AML
Vadastuximab talirine in combination for newly diagnosed AML
Remissions following anti-CD22 CAR therapy in children with relapsed ALL
Subgroup analysis of elderly high risk AML patients receiving CPX-351
A new spin on leukaemia therapy
Anti CD22 CAR T cell therapy for relapsed paediatric ALL
CPX-351 after stem cell transplant for elderly patients with AML
International Aspirin Foundation Senior Science Award winner
Treatment of primary thyroid cancers
Editor's Choice for November 2016
Surgery and social risk factors in Pakistan